ATNX Athenex Inc

On December 21, 2021, Simon Pedder notified Athenex, Inc. (the “Company”) that he will be resigning from his position as Chief Business and Strategy Officer, Proprietary Products, effective as of December 31, 2021. In connection with his resignation, the Company and Dr. Pedder entered into a consulting agreement effective as of January 1, 2022, pursuant to which Dr. Pedder will provide clinical development and business development related services to the Company until July 1, 2022, unless earlier terminated. Under that agreement, Dr. Pedder is entitled to receive $350 per hour for providing consulting services. The foregoing description of the agreement is a summary of its material terms, does not purport to be complete, and is qualified in its entirety by reference to the agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On December 22, 2021, the Company appointed Timothy Cook as Chief Business and Commercial Officer, Proprietary Drugs. Mr. Cook, age 59, has been serving as the Company’s Senior Vice President of Global Oncology since July 2018. Prior to joining the Company, Mr. Cook served as the Vice President and Chief Operating Officer for Lilly Oncology from February 2017 until December 2017 after serving in various roles of increasing responsibility beginning in November 2000.

Mr. Cook’s compensation from the Company did not change in connection with his appointment to Chief Business and Commercial Officer, Proprietary Drugs. Mr. Cook is eligible to receive a base salary of approximately $350,000 per year and a target annual cash incentive award equal to 40% of his base salary.

Mr. Cook was not appointed to this position pursuant to any arrangement or understanding with any person. Neither Mr. Cook nor any of his immediate family has been a party to any transaction with the Company, nor is any such transaction currently proposed, that would be reportable under Item 404(a) of Regulation S-K.